Lab-grown embryo models are getting more realistic. Scientists are getting more concerned
Scientists are exploring ways to mimic the origins of human life without two fundamental components: sperm and egg.
They are coaxing clusters of stem cells – programmable cells that can transform into many different specialized cell types – to form laboratory-grown structures that resemble human embryos.
These embryo models are far from perfect replicas. But as labs compete to grow the best likeness, the structures are becoming increasingly complex, looking and behaving in some way as embryos would.
The structures could further the study of human development and the causes infertility. However, the dizzying pace of the research, which started little more than a decade ago, is posing ethical, legal and regulatory challenges for the field of developmental biology.
'We could have never anticipated the science would have just progressed like this. It's incredible, it's been transformative how quickly the field has moved, said Amander Clark, a professor of molecular cell and developmental biology at the University of California, Los Angeles, and the founding director of the UCLA Center for Reproductive Science, Health and Education. 'However, as these models advance, it is crucial that they are studied in a framework that balances scientific progress with ethical, legal and social considerations.'
Clark is co-chair of the International Society of Stem Cell Research (ISSCR) Embryo Models Working Group, which is now trying to update such a framework on a global scale. At issue is the question of how far researchers could go with these stem cells, given time and the right conditions. Could scientists eventually replicate an actual embryo that has a heartbeat and experiences pain, or one that could grow into a fully developed human model?
Embryo models: How realistic are they?
As current research stands, no model mimics the development of a human embryo in its entirety — nor is any model suspected of having the potential to form a fetus, the next stage in human development equivalent to week 8 or day 56 in a human pregnancy. Creating embryo models has also been a hit-and-miss process for most research groups, with only a small percentage of stem cells going on to self-organize into embryo-like structures.
However, the models do exhibit several internal features and cell types that an embryo needs to develop, such as the amnion, yolk sac and primitive streak, and that could, 'with future improvements, eventually progress toward later embryo structures including heart, brain, and other organ rudiments,' according to a June paper coauthored by Clark and published in the journal Stem Cell Reports. Similar models made with mouse cells have reached the point where the brain begins to develop and a heart forms.
Critically, the goal isn't to develop these models into viable fetuses, ultimately capable of human sentience, but to develop a useful research tool that unlocks the mysteries of how a human cell divides and reproduces to become a human body. The models also make way for experiments that can't be performed on donated embryos in a lab. However, it's possible as research advances that the distinction between a lab-grown model and a living human embryo could become blurred.
And because the models lie at the intersection of historically controversial fields — stem cell biology and embryology — the work merits closer oversight than other forms of scientific research, Clark said.
Clark and the ISSCR's Embryo Models Working Group in June recommended enhanced oversight of research involving the models. The society's guidelines, which first included guidance on embryo models in 2021, are being revised to incorporate the recommendations of the group and will be released in a few weeks.
The current ISSCR guidelines make a distinction between 'integrated embryo models' that replicate the entire embryo, and 'non-integrated models' that replicate just one part of an embryo, requiring stricter oversight of the former. The updated guidelines will instead recommend that all research involving both types of embryo models should undergo 'appropriate ethical and scientific review.'
The proposed update will also set out two red lines: The current guidance already prohibits the transfer of human embryo models into a human or animal uterus. The updated version will also advise scientists not use human embryo models to pursue ectogenesis: the development of an embryo outside the human body via the use of artificial wombs — essentially creating life from scratch.
According to Clark, the stem cell-based embryo models she and other research teams work on should be considered distinct from research on actual human embryos, usually surplus IVF embryos donated to science. Such research is tightly regulated in many countries, and banned in others, including Germany, Austria and Italy.
It makes sense, at least for now, to treat models and real embryos differently, said Emma Cave, a professor of healthcare law at Durham University in the UK who works on embryo models. She uses diamonds as an analogy: Natural diamonds and their commercially lab-grown equivalents are made from the same chemical components, but society assigns them different values. She cautioned there shouldn't be a rush to regulate embryo models too quickly in case it shuts down promising research.
'We are at an early stage in their development, where it could be that in 5, 10, 15, 20 years, that they could look very like a human embryo, or it might be they never get to that stage,' she said.
Embryo Scientists
Scientists look at a model of an early-stage human embryo created by Israeli scientists at the Weizmann Institute of Science in Rehovot, Israel, September 7, 2023. (Amir Cohen/Reuters via CNN Newsource)
A 'Turing test' for embryo models
As the scientific research unfolds, oversight of embryo models is taking different shapes in different jurisdictions. Australia has taken the strictest approach. It includes embryo models within the regulatory framework that governs the use of human embryos, requiring a special permit for research.
The Netherlands in 2023 similarly proposed treating 'non-conventional embryos' the same as human embryos in the eyes of the law. The proposal is still under discussion, according to the Health Council of the Netherlands.
Researchers in the United Kingdom released a voluntary code of conduct in 2024, and Japan has also issued new guidelines governing research in the field.
In the United States, embryo models aren't covered by any specific legal framework, and research proposals are considered by individual institutions and funding bodies, Clark noted. The National Institutes of Health said in 2021 that it would consider applications for public funding of research into embryo models on a case-by-case basis and monitor developments to understand the capabilities of these models.
Few other countries, however, appear poised to adopt specific legislation on embryo models, making the guidelines issued by the ISSCR a 'highly influential' reference for researchers around the world, according to the Nuffield Council on Bioethics, a London-based organization that advises on ethical issues in biomedicine.
The council said in a November 2024 report that international guidelines were key to avoid 'research being carried out that does not meet high ethical and scientific standards; this in turn could impact on the national public perception of risk, leading to a more risk-averse approach that hinders responsible scientific development.'
Clark said the ISSCR's updated voluntary guidelines would help scientific funding bodies around the world better evaluate applications and publishers of research understand whether work was performed in an ethically responsible way, particularly in places where the law or other guidelines don't take embryo models into account.
The future challenge for regulators is to understand when and whether an embryo model would be functionally the same as a human embryo and therefore potentially afforded the same or similar protection as those surrounding human embryos, said Naomi Moris, group leader at The Francis Crick Institute's developmental models laboratory. The only definitive test would be to transfer the model into the uterus of a surrogate, a move that's forbidden by current bioethical standards.
However, Moris is among a group of researchers that has proposed to two tipping points or 'Turing tests' — inspired by computer scientist Alan Turing's way of determining whether machines can think like humans — to evaluate when distinctions between a lab-gown model and a human embryo would disappear.
'These things are not embryos at the moment, they clearly don't have the same capacity as an embryo does. But how would we know ahead of time that we were approaching that?' Moris said. 'That was the logic behind it. What metrics would we use as a kind of proxy for the potential of an embryo model that might then suggest that it was at least approaching the same sorts of equivalency as an embryo.'
The first test would measure whether the models can be consistently produced and faithfully develop over a given period as normal embryos would. The second test would assess when animal stem cell embryo models — particularly animals closest to humans such as monkeys — show the potential to form living and fertile animals when transferred into surrogate animal wombs, thus suggesting that the same outcome would in theory be possible for human embryo models.
That hasn't happened yet, but Chinese researchers in 2023 created embryo models from the stem cells of macaque monkeys that when implanted in a surrogate monkey triggered signs of early pregnancy.
Embryo ethics: A delicate dance
Proponents of the technology say the models offer an equally, and possibly more, useful, ethical alternative to research on scarce and precious human embryos. The models have the potential to be produced at scale in a lab to screen drugs for embryo toxicology, a impactful application given that pregnant women have often been excluded from drug trials because of safety concerns.
Lab based embryo models
A 3D-printed replica of a human embryo model on display as part of an exhibit by The Francis Crick Institute at the Royal Society's Summer Science Exhibition in London earlier this month. The replica is about 500 times bigger than the actual embryo model, which was 0.3 millimeters. (Stephen Potvin via CNN Newsource)
Yet, the potential for these models to be used in the creation of life has been cause for worry among bioethicists. 'There are commercial and other groups raising the possibility of building an embryo in vitro and combining different bioengineering approaches to bring such an entity to viability,' according to the June paper coauthored by Clark and other members of the ISSCR's embryo model working group.
'Currently the practice of bringing an SCBEM (stem cell-based embryo model) to viability is considered unsafe and unethical and should not be pursued,' the study noted.
Cave said ectogenesis may sound like the realm of science fiction, but it isn't impossible. As embryo models continue to be developed, and separate research is advancing into artificial wombs, the two technologies could meet, Cave said.
The challenge, she added, is recognizing the value of these research paths but at the same time preventing misuse.
Jun Wu, an associate professor at the Department of Molecular Biology at the University of Texas Southwestern is one of a number of stem cell biologists involved in the field. He agreed that ectogenesis should be off the table but explained that researchers developing embryo models must engage in a delicate dance: To the unlock the mysteries of the human embryo, models have to resemble embryos closely enough to offer real insight but they must not resemble them so closely that they risk being viewed as viable.
'The big black box' — and a breakthrough
Magdalena Zernicka-Goetz, the Bren professor of biology and biological engineering at Caltech, said she welcomed the new guidelines.
She announced in 2023 that her team had succeeded in a world first: growing embryo-like models to a stage resembling 14-day-old embryos. Later the same year, Jacob Hanna, a professor of stem cell biology and embryology at the Weizmann Institute of Science in Israel, said his team had gone a step further with a model derived from skin cells that showed all the cell types that are essential for an embryo's development — including the precursor of the placenta.
Together the work represented a breakthrough for the models' potential use in research on pregnancy loss: At 14 days the human embryo has begun to attach to the lining of the uterus, a process known as implantation. Many miscarriages occur around this stage, Zernicka-Geotz said.
Lab research on human embryos beyond 14 days, including those donated from IVF treatments, is prohibited in most jurisdictions. And while some scientists do study tissue obtained from abortions, such tissue is limited because few procedures take place between week 2 and week 4 of an embryo's development.
The ability to grow an embryo model outside of a womb at this developmental stage paves the way for studies that are not possible in living human embryos.
'Far more pregnancies fail than succeed during the critical window just before, during and immediately after implantation. This is why we created in my lab the embryo-like structures from stem cells as a way to really understand this critical and so highly fragile stage of development,' Zernicka-Goetz said.
Clark agreed that embryo models could potentially be used to address infertility problems: 'Implantation. It's the big black box. Once the embryo implants in the uterus, we understand very little about the development,' Clark added.
'And if we can't study it, we don't know what we're missing.'
By Katie Hunt, CNN
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Globe and Mail
4 hours ago
- Globe and Mail
Vor Bio Appoints Seasoned Biotech Executive Dallan Murray as Chief Commercial Officer
CAMBRIDGE, Mass., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced the appointment of Dallan Murray as Chief Commercial Officer, effective immediately. 'We're thrilled to welcome Dallan to Vor Bio at this important inflection point,' said Jean-Paul Kress, M.D., Chief Executive Officer and Chairman of the Board. 'His track record of building high-performing commercial organizations and executing successful product launches will be instrumental as we prepare for potential commercialization of telitacicept and shape our broader growth strategy.' Mr. Murray brings more than 25 years of experience leading commercial strategy, global product launches, and customer-facing organizations in biotechnology and pharmaceutical companies. He joins Vor Bio from Sarepta Therapeutics, where he most recently served as Executive Vice President, Chief Customer Officer. In that role, he led the commercial and medical affairs organizations, along with the international business unit. Under his leadership, Sarepta achieved approximately $1.8 billion in net product revenue in 2024. While at Sarepta he oversaw multiple product launches, including the launch of the first RNA therapy and first gene therapy for duchenne muscular dystrophy. Over the course of his career, Mr. Murray has led or supported more than a dozen product launches, including INCIVEK at Vertex Pharmaceutics, Inc., the fastest launch to $1 billion in biotech history at the time, and multiple global rollouts at Gilead Sciences, Inc., Biogen Inc., and Johnson & Johnson. At Gilead, he oversaw the launch of VIREAD in hepatitis B and maintained leadership in the HBV market. While at Biogen, he played a key role in the reintroduction and global commercialization of TYSABRI for multiple sclerosis, helping drive adoption across North America and international markets. Mr. Murray holds an MBA from Queen's University in Ontario, Canada, and a Bachelor of Commerce from the University of Alberta. 'Vor Bio is building a company with great potential,' said Mr. Murray. 'With telitacicept already approved in China for multiple autoimmune indications and now advancing through global Phase 3 development, I look forward to the opportunity to bring a much-needed treatment to patients around the world. I'm excited to join the team and help lay the commercial and strategic foundation for long-term success.' About Vor Bio Vor Bio is a clinical-stage biotechnology company transforming the treatment of autoimmune diseases. The Company is focused on rapidly advancing telitacicept, a novel dual-target fusion protein, through Phase 3 clinical development and commercialization to address serious autoantibody-driven conditions worldwide. For more information visit Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The words 'aim,' 'anticipate,' 'can,' 'continue,' 'could,' 'design,' 'enable,' 'expect,' 'initiate,' 'intend,' 'may,' 'on-track,' 'ongoing,' 'plan,' 'potential,' 'should,' 'target,' 'update,' 'will,' 'would,' and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Forward-looking statements in this press release include Vor Bio's statements regarding Vor Bio's development and commercialization plans for telitacicept, its ability to change the treatment landscape for patients with autoimmune conditions and other statements that are not historical fact. Vor Bio may not actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various factors. These and other risks are described in greater detail under the caption 'Risk Factors' included in Vor Bio's most recent annual or quarterly report and in other reports it has filed or may file with the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and Vor Bio expressly disclaims any obligation to update any forward-looking statements, whether because of new information, future events or otherwise, except as may be required by law.


Globe and Mail
4 hours ago
- Globe and Mail
NeOnc Technologies Featured on Yahoo Finance's Podcast Trader Talk: AI and Biotech Take on Brain Cancer
CALABASAS, Calif., Aug. 04, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI), a multi-phase 2 clinical-stage biotechnology company advancing transformative treatments for brain and central nervous system cancers, was featured on Yahoo Finance's Trader Talk with Kenny Polcari in a podcast episode titled 'AI and Biotech Take on Brain Cancer.' As Trader Talk describes it: 'When a biotech startup lands in a major index just months after its IPO, investors take notice. In this episode of Trader Talk, Kenny Polcari speaks with Amir Heshmatpour, executive chairman and president of NeOnc Technologies (Nasdaq: NTHI), about how the company defied a tough market to go public, secure a $50 million partnership in the Middle East, and join the Russell Microcap Index. Heshmatpour explains NeOnc's focus on intranasal drug delivery for brain cancer, the significance of its partnership with USC's medical school, and how global clinical trials are expanding the company's reach. The conversation also includes how AI and quantum computing could transform the biotech industry. It's a rare behind-the-scenes look at how a small-cap biotech is executing on a global stage.' You can tune in to the episode on Apple Podcasts, Spotify, YouTube, or wherever you listen to your podcasts. ABOUT NEONC TECHNOLOGIES HOLDINGS, INC. NeOnc Technologies Holdings, Inc. is a clinical-stage life sciences company focused on the development and commercialization of central nervous system therapeutics that are designed to address the persistent challenges in overcoming the blood-brain barrier. The company's NEO ™ drug development platform has produced a portfolio of novel drug candidates and delivery methods with patent protections extending to 2038. These proprietary chemotherapy agents have demonstrated positive effects in laboratory tests on various types of cancers and in clinical trials treating malignant gliomas. NeOnc's NEO100 ™ and NEO212 ™ therapeutics are in Phase II human clinical trials and are advancing under FDA Fast-Track and Investigational New Drug (IND) status. The company has exclusively licensed an extensive worldwide patent portfolio from the University of Southern California consisting of issued patents and pending applications related to NEO100, NEO212, and other products from the NeOnc patent family for multiple uses, including oncological and neurological conditions. For more about NeOnc and its pioneering technology, visit Important Cautions Regarding Forward Looking Statements This press release contains 'forward-looking statements' within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements can be identified by terminology such as 'may,' 'will,' 'should,' 'intend,' 'expect,' 'plan,' 'budget,' 'forecast,' 'anticipate,' 'believe,' 'estimate,' 'predict,' 'potential,' 'continue,' 'evaluating,' or similar words. Statements that contain these words should be read carefully, as they discuss our future expectations, projections of future results of operations or financial condition, or other forward-looking information. Examples of forward-looking statements include, among others, statements regarding whether a definitive agreement will be reached with Quazar. These statements reflect our current expectations based on information available at this time, but future events may differ materially from those anticipated. The 'Risk Factors' section of our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, along with other cautionary language in that report or in our subsequent filings, outlines important risks and uncertainties. These may cause our actual results to differ materially from the forward-looking statements herein, including but not limited to the failure to finalize the agreement with Quazar, modifications to its terms, or alternative uses of proceeds. We assume no obligation to revise or update any forward-looking statements, whether as a result of new information, future developments, or otherwise, except as required by applicable securities laws and regulations. 'NEO100' and NEO '212' are registered trademarks of NeOnc Technologies Holdings, Inc.


National Post
7 hours ago
- National Post
Why beans can be hard to digest, and what a Sask. researcher is doing about it
As humans, we've gone to great lengths to overcome legumes ' natural defences. We have the tenacity of our forebears to thank every time we fill a bowl with chili or swipe refried beans with a tortilla. Take lupins, which require boiling and washing for a week while frequently changing the water to make them palatable. Even then, they don't soften, but no need to worry. Do as the Italians do and pop them like olives as a bar snack. Article content Article content For less needy legumes, such as pinto beans or chickpeas, the question of whether to soak or not often rears its head. There are supporters in both camps, and though it's not strictly necessary, there's one compelling reason to soak beans and peas: digestibility. Article content Article content Legumes contain 'antinutrients,' such as oligosaccharides — the reason beans can't shake the 'musical fruit' moniker — that prevent animals (including humans) from fully digesting them. Soaking helps reduce these compounds, making legumes more digestible. Article content With a little bit of planning, soaking is perfectly doable at home. (Forethought isn't always required to enjoy beans, of course. Just open a can.) But it complicates things in an industrial setting, says Tolen Moirangthem, a PhD student at the University of Saskatchewan (USask) College of Engineering and the lead author of a recent study published in Innovative Food Science & Emerging Technologies that found a better method with big potential. Article content Article content Soaking beans overnight — 'even two days, let it ferment a little bit' — does the trick at home, says Moirangthem. But on an industrial scale, with multiple tons of legumes, that's a huge amount of time and risk. 'If water is involved, there are microbes coming in, there's bacteria coming in, all sorts of stuff coming in. So if anything goes wrong, my entire sample is off. It's gone,' says Moirangthem. Article content Article content 'We're always looking for an alternative. Is it less time-consuming, faster, easier to handle? Those are the things that matter when it comes to scaling up.' Article content Moirangthem and a team of researchers from the USask Department of Chemical and Biological Engineering devised a heating method using radio frequency (RF) waves. Instead of up to two days, their process takes five minutes. In addition to being efficient, it's also more effective at reducing antinutrients and eliminating negative flavours than current techniques. Article content The large ovens that food processing companies currently use to heat beans and peas can burn the outside of the legumes before the inside is hot enough to deactivate the antinutrients. The USask researchers found that their selective heating method, which Moirangthem compares to microwaves, reduced the amount of an antinutrient (trypsin inhibitors, proteins) by 81 per cent. Article content Since their method works without water, there's no soaking or boiling. 'We're trying to explore how we can do it in a dry way,' says Moirangthem. The goal is to produce a digestible, plant-based protein that can be used as an ingredient in burger patties and protein powders and added as a flour in bakeries. Article content Moirangthem has been studying food for the past 15 years, driven by a mission to bolster food security. 'With the global population increasing at this exponential rate, there will be times, in the near future, that we don't have enough food for people,' he says. 'How can we fight this? How can we (make sure) everybody gets a little bit to eat, at least to survive, and it has to be nutritious.' Article content He sees potential in legumes to meet the world's protein needs cost-effectively and sustainably. Since dairy and meat are perishable, they're more fragile to work with, Moirangthem highlights. On the other hand, dried peas and beans are non-perishable, have a long shelf life and 'can still deliver similar nutritional protein content.' Article content With all their promise, Moirangthem adds that legumes present a few challenges. For one, the functional properties of the protein. 'It's way easier to make a dairy-based protein supplement or dairy-based protein product because the functional property supports product manufacturing, and it doesn't require a lot of processing before we can utilize it.' Plant-based protein takes more work. 'We're trying to find how we can enhance the functional properties of proteins in beans so that we can actually go on par with (animal protein).' Article content Then, there's digestibility and the issue of antinutritional properties, which interfere with our ability to absorb all of the legumes' nutrients. Article content Moirangthem's research has shown that antinutrients can be reduced using RF heating. 'My study just scratched the surface, but it has potential.' He plans to continue researching the method and explore what other food processing operations it could replace. He also wants to go deeper into antinutrients and study the effect of RF heating on specific properties. Article content Article content Moirangthem highlights that Canada's ample farmland could make it a global nutrition hub. 'If we come together and invest in the right places and work on the right ideas, I think we can do a lot of good things,' he says, noting that he'd like to see more collaboration between academia and industry. Article content 'Otherwise, all the research we do in the lab remains in the lab. We need to work hand in hand, and government policies to encourage such projects or such sustainable approaches would be a good stepping stone.' Article content Should you soak your beans? Article content Radio frequency machines like the one Moirangthem and his colleagues use in the lab are meant for industrial use. 'It's a huge setup.' So, what's the best way to ensure that the legumes you cook from dried at home are as digestible as possible? Article content 'The best thing is traditional, very traditional, and easy to do. Soak it in water for a couple of days (at room temperature). That's it,' says Moirangthem. Cooks in his native India push it even further, fermenting legume-based batters for dishes such as dosa or idli. 'It's very easily digested.'